Available to passage freely in academic laboratory
for $1,000 per model.*
Receive 5 NSG™ mice at no additional cost for
each PDX Live™ model purchased.**
Highly characterized, clinically relevant models.
|Study Type||Arms||Vehicle||SOC||Drug A||Drug B||Combination
|1. Pilot efficacy study
|2. Dose response||5||1||1||3||0||0|
|3. Drug combination||4||1||0||1||1||1|
Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.
3A. 3B. 3C.
Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)
Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.
Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).